05:14 AM EDT, 10/19/2026 (MT Newswires) -- Hemogenyx Pharmaceuticals (HEMO.L) partnered with Japan's Nitto Denko to explore whether the latter's cell-targeted lipid nanoparticle drug delivery technology could be used to deliver its messenger RNA encoding its FLT3-targeting chimeric antigen receptor to human T cells. Subject to the study's success, the London-listed biopharmaceutical company would be able to convert its CAR-T technology into a drug-like, off-the-shelf product, making it easier to manufacture, store and distribute than traditional autologous CAR-T therapy, according to a Monday filing. The study is an in vitro evaluation and is expected to take four months. It will not affect Hemogenyx's ongoing phase 1 clinical trial of HG-CT-1 in relapsed/refractory acute myeloid leukemia.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.